Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia

Cellectar Biosciences

Cellectar Biosciences

CLRB

0.00
  • Cellectar BioSciences outlined plans to seek US accelerated approval for iopofosine I 131 in Waldenström macroglobulinemia in 1H27.
  • Phase 3 confirmatory trial planned with first patient enrollment projected for 1Q27; potential approval targeted for 4Q27 or 1Q28.
  • Phase 2b CLOVER-WaM data showed major response rate 61.8%, overall response rate 83.6%, disease control rate 98.2% in 55 evaluable patients.
  • Median duration of response 533 days; median progression-free survival 406 days, based on a Dec 2025 data cutoff.
  • Phase 3 design targets 200 patients; estimated total study cost USD 42 million, including about USD 15 million to accelerated approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.